Bipolar disorder

On this page

Quick Overview

Bipolar disorder is a severe mental illness characterized by episodic mood disturbances with manic/hypomanic and depressive episodes. NICE CG185 provides evidence-based guidance for acute management and long-term relapse prevention. Critical for UK Medical PG: recognize rapid cycling (≥4 episodes/year), understand mood stabilizer selection hierarchy, and implement structured monitoring protocols.

Core Facts & Concepts

Diagnostic Criteria:

  • Mania: Elevated/irritable mood ≥7 days (or any duration if hospitalization required) + ≥3 symptoms (grandiosity, decreased sleep, pressured speech, flight of ideas, distractibility, increased goal-directed activity, risk-taking)
  • Hypomania: Similar but ≥4 days duration, less severe, no psychotic features, no hospitalization
  • Bipolar I: ≥1 manic episode (with/without depression)
  • Bipolar II: ≥1 hypomanic + ≥1 major depressive episode
  • Rapid cycling: ≥4 mood episodes within 12 months (poorer prognosis, requires treatment modification)

Figure 1: Clinical presentation of acute mania showing hyperactivity and pressured speech

NICE CG185 Mood Stabilizer Hierarchy:

LineAcute ManiaBipolar DepressionLong-term Maintenance
1stHaloperidol, olanzapine, quetiapine, or risperidoneFluoxetine + olanzapine or quetiapine aloneLithium (first choice)
2ndLithium (if 1st line ineffective)Lamotrigine or lithiumValproate or olanzapine
3rdValproate (acute only, not women of childbearing potential)Consider lamotrigine + lithiumLamotrigine (especially for preventing depression)

Key Dosing Thresholds:

  • 💊 Lithium: Target plasma level 0.6-1.0 mmol/L (maintenance); check at 12h post-dose
  • 💊 Valproate: CONTRAINDICATED in women of childbearing potential (teratogenic)
  • 💊 Lamotrigine: Titrate slowly (risk Stevens-Johnson syndrome); start 25mg daily, increase over 6 weeks

Figure 2: Lithium therapy monitoring flowchart showing target range 0.6-1.0 mmol/L

Problem-Solving Approach

Acute Mania Management (NICE CG185):

  1. Risk assessment first: Assess harm to self/others, safeguarding needs, capacity
  2. Stop antidepressants if currently prescribed (can worsen mania)
  3. First-line options (choose based on patient factors):
    • Antipsychotic monotherapy: Haloperidol 1.5-3mg/day, olanzapine 15mg/day, quetiapine 300-800mg/day, or risperidone 2-6mg/day
    • If already on lithium with subtherapeutic levels: optimize dose first
  4. Consider combination if partial response at 7-14 days: antipsychotic + lithium or valproate
  5. Benzodiazepines (e.g., lorazepam 1-2mg) for short-term behavioral control/insomnia

Bipolar Depression Management:

  1. Review current medication: Optimize mood stabilizer dose if subtherapeutic
  2. Psychological intervention: CBT or interpersonal therapy (mild-moderate depression)
  3. First-line pharmacological: Fluoxetine 20-60mg + olanzapine 5-20mg OR quetiapine 300mg/day
  4. Avoid antidepressant monotherapy (risk of manic switch ~15-20%)
  5. If treatment-resistant: Consider lamotrigine augmentation

⚠️ Warning: Antidepressant monotherapy in bipolar depression increases manic switch risk. Always use with mood stabilizer or use quetiapine/olanzapine+fluoxetine.

Red Flags 🚩:

  • Rapid cycling pattern → worse prognosis, review thyroid function, consider valproate/lamotrigine
  • Non-adherence → commonest cause of relapse (60-70% lifetime non-adherence rate)
  • Substance misuse → co-occurs in 40-60%, worsens outcomes

Analysis Framework

Rapid Cycling Identification & Management:

  • Definition: ≥4 episodes (manic/hypomanic/depressive) in 12 months
  • Prevalence: 10-20% of bipolar patients
  • Management differences: Avoid antidepressants, prefer valproate or lamotrigine over lithium

Mood Stabilizer Selection Criteria:

FactorLithiumValproateLamotrigineAntipsychotics
Acute mania+++++-+++
Bipolar depression+-+++++ (quetiapine/olanzapine)
Maintenance+++ (best evidence)++++ (prevents depression)++
Rapid cycling++++++
Pregnancy safetyContraindicated 1st trimesterAbsolutely contraindicatedRelatively saferVariable
Monitoring burdenHigh (levels, renal, thyroid)ModerateLowModerate (metabolic)

Discriminating Features - Mania vs Agitated Depression:

  • Mania: Elevated/expansive mood, grandiosity, decreased need for sleep (not just insomnia)
  • Agitated depression: Low mood predominates, psychomotor agitation without euphoria, guilt/worthlessness

Visual Aid

Long-term Monitoring Requirements:

MedicationBaselineOngoing Monitoring
LithiumU&Es, TFTs, BMI, ECG if cardiac riskLithium level weekly until stable then q3mo; U&Es/TFTs q6mo; weight q1yr
ValproateLFTs, FBC, pregnancy testLFTs/FBC at 6mo then annually; teratogenicity counseling mandatory
LamotrigineNone specificRash monitoring (especially weeks 2-8); no routine bloods
AntipsychoticsWeight, BMI, lipids, glucose, prolactinWeight/BMI q3mo for 1yr then annually; lipids/glucose annually

Key Points Summary

Bipolar I vs II: Mania (≥7 days, severe) vs hypomania (≥4 days, milder); both can have depression

Acute mania first-line (NICE CG185): Antipsychotic monotherapy (haloperidol/olanzapine/quetiapine/risperidone) OR optimize lithium if already prescribed

Bipolar depression first-line: Fluoxetine + olanzapine OR quetiapine monotherapy; never antidepressant alone (manic switch risk)

Maintenance gold standard: Lithium 0.6-1.0 mmol/L (check 12h post-dose, q3mo when stable); monitor U&Es/TFTs q6mo

Rapid cycling (≥4 episodes/year): Consider valproate or lamotrigine over lithium; avoid antidepressants

Valproate: Absolutely contraindicated in women of childbearing potential (teratogenic); use only if pregnancy prevention program in place

Relapse prevention: Structured monitoring, medication adherence support (60-70% lifetime non-adherence), psychological interventions (CBT), early warning signs education

📌 Remember: LITHIUM monitoring - Levels (q3mo), Thyroid (q6mo), U&Es (q6mo), Weight (annually)

Practice Questions: Bipolar disorder

Test your understanding with these related questions

A 58-year-old man presents with progressive memory loss and behavioral changes over 10 months. MRI shows asymmetric frontotemporal atrophy. What is the most appropriate symptomatic treatment?

1 of 5

Flashcards: Bipolar disorder

1/10

_____ is associate with a poorer prognosis in Schizophrenia

Hint: Onset

TAP TO REVEAL ANSWER

_____ is associate with a poorer prognosis in Schizophrenia

Gradual

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial